Hwasun-gun Signs Investment Agreement to Establish Manufacturing Facility for In Vitro Diagnostic Medical Devices View original image


[Hwasun=Asia Economy Honam Reporting Headquarters Reporter Kim Young-gyun] Jeonnam Hwasun-gun (Governor Gu Chung-gon) and the Jeonnam Bio Industry Promotion Foundation Biopharmaceutical Center (Director Kwak Won-jae) signed a joint investment agreement on the 19th at the Biopharmaceutical Research Center with Medicloud Co., Ltd. (CEO Kim Byung-yang), a manufacturer of in vitro diagnostic medical devices, for an investment of 3 billion KRW and employment of 15 people.


According to the county on the 20th, Medicloud Co., Ltd. is a promising company that provides customized data information services through a gene analysis-based disease prediction service platform and is rapidly growing in domestic and international markets, recently entering the Chinese and Japanese markets.


Through this investment agreement, Medicloud Co., Ltd. plans to establish a GMP facility for medical device manufacturing within the Biopharmaceutical Research Center and commercialize a molecular diagnostic-based COVID-19 diagnostic kit business.


The county expects to revitalize the Hwasun Vaccine Industry Special Zone by expanding businesses in precision medicine and genomic molecular diagnostics in the future.



According to the agreement, the county and the Biopharmaceutical Research Center plan to actively support Medicloud Co., Ltd.'s development of molecular diagnostic-based in vitro diagnostic kits to enhance the competitiveness of the Hwasun Vaccine Industry Special Zone and promote regional economic revitalization.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing